Investor Relations
Company Profile
ResApp Health Limited (ASX:RAP) is developing healthcare solutions to assist doctors and empower patients to diagnose and manage respiratory disease on smartphones without the need for additional hardware. ResApp’s core technology uses sound to diagnose respiratory diseases including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease and asthma.
Headquarters
Level 8, 127 Creek St
Brisbane, QLD 4000
Registered Office
Level 24, 44 St Georges Tce
Perth, WA 6000
Board of Directors
Dr Roger Aston – Non-Executive Chairman
Dr Tony Keating – Chief Executive Officer and Managing Director
Nathan Buzza – Non-Executive Director
Chris Ntoumenopoulos – Non-Executive Director
Listing
Australian Securities Exchange
ASX code: RAP
Share price
Please refer to the ASX website for current share price and history.
Share Registry
Link Market Services Limited
Level 12 QV1 Building
250 St Georges Terrace
Perth WA 6000
Investor Relations Contact
Brian Leedman
VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000
CONTACT US
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations
LEGAL
Terms of Use
Privacy Policy
ResAppDx-US is pending review of a request for De Novo classification and is not available for sale in the United States.
© 2019 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries.